References in periodicals archive ?
DuBois' laboratory where the purpose of the research was to explore the potential anti-tumor effects of polmacoxib (formerly CG100649), CrystalGenomics' novel Non-Steroidal Anti-Inflammatory Drug (NSAID) candidate with its NDA pending for an approval by the MFDS of South Korea for the relief of signs and symptoms of osteoarthritis.
Also, CrystalGenomics has recently obtained a phase 2 study protocol approval from the MFDS for its molecular targeted anti-cancer therapeutic.
The NDA for Acelex was approved by the Korean MFDS last week.
We are pleased G-treeBNT has filed an IND this year with MFDS as they stated they would last March when we entered into the partnership.
Acronyms browser ?
Full browser ?